Revvity (RVTY) Stock Price & Analysis
RVTY Stock Chart & Stats
- Day’s Range
- MXN 1,910.00 - MXN 2,235.19
- 52-Week Range
- MXN 1,644.85 - MXN 2,235.19
- Previous Close
- MXN 1,910.00
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- MXN 329.22B
- Enterprise Value
- MXN 15.02B
- Total Cash (Recent Filing)
- MXN 1.02B
- Total Debt (Recent Filing)
- MXN 3.34B
- Price to Earnings (P/E)
- 74.8
- Beta
- -0.08
- Next Earnings
- Nov 03, 2026 (Est.)
- EPS Estimate
- 24.37
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 0.18%
Bulls Say, Bears Say
Bulls Say
Diagnostics Growth
Diagnostics is showing broad, sustained demand across reproductive health and immunodiagnostics, providing a durable growth engine within the portfolio. This strength can support recurring testing-related consumables and services while offsetting weaker areas of the business.
Cash Generation And Deleveraging
Strong free cash flow conversion gives Revvity internal funding for product investment, acquisitions and debt reduction. Retiring debt while targeting net leverage near 2x should improve financial flexibility and reduce balance-sheet constraints over the next several quarters.
Instrument And Software Innovation
Double-digit screening order growth, a multi-year-high backlog and expanding software capabilities indicate strengthening customer adoption of Revvity workflows. A broader instrument, software and informatics ecosystem can deepen customer relationships and support recurring revenue.
Bears Say
Margin Compression And Earnings Volatility
Although current profitability is solid, margins remain well below earlier-cycle levels and historical earnings have been uneven. This limits the predictability of long-term earnings power and leaves less operating cushion if demand or business mix becomes less favorable.
Signals Software Weakness
The sharp Signals decline shows that software revenue remains exposed to contract timing and comparison effects, despite management expecting recovery. Continued volatility could make growth less predictable and weaken the contribution of a potentially recurring, high-value business.
China Immunodiagnostics Divestiture
Exiting China Immunodiagnostics may streamline the portfolio, but it also removes an established revenue contribution and reflects structural difficulty in that market. Until closing, the business remains in reported results, creating a prolonged transition in geographic mix.
Revvity News
RVTY FAQ
What was Revvity’s price range in the past 12 months?
What is Revvity’s market cap?
When is Revvity’s upcoming earnings report date?
How were Revvity’s earnings last quarter?
Is Revvity overvalued?
Does Revvity pay dividends?
What is Revvity’s EPS estimate?
How many shares outstanding does Revvity have?
What happened to Revvity’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Revvity?
What is the TipRanks Smart Score and how is it calculated?
Revvity Stock Smart Score
Company Description
Revvity
Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Prahlad R. Singh
- Employees
- 11,000
- Website
- www.revvity.com
- Address
- 77 4th Avenue, Waltham, MA, 02451, US
Revvity (RVTY) Earnings & Revenues
RVTY Company Deck
RVTY Earnings Call
Earnings Call SentimentPositive
The call presented a generally positive operational and financial picture: revenue and EPS beat with upgraded full-year guidance, strong Diagnostics performance, accelerating high-content instrument orders and robust cash flow and balance sheet improvements. Key near-term weaknesses include a sizable decline in Signals software revenue this quarter, some production/timing constraints that shifted instrument revenue into Q3, and portions of the quarter's outperformance tied to one-time tariff refunds and tax timing. Management plans reinvestments of a portion of one-time benefits while highlighting new software capabilities and AI-driven demand as multi-year growth drivers—though the AI opportunity is still early and not fully quantifiable.
View all MX:RVTY earnings summariesRVTY Net sales Breakdown
- 50.11% Life sciences
- 49.89% Diagnostics
RVTY Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 0 | 3 |
| Technical Analysis | 5 | 0 | 1 |
| Moving Averages | 10 | 0 | 2 |
